{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-022875","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2026-05-14T12:00:42+00:00","discovered_at":"2026-05-14T12:05:00.583021+00:00","generated_at":"2026-05-14T12:10:23.339612+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Biofrontera Q1 revenue up 17% to $10.1M; gross margin 80%; PDUFA for sBCC set Sept 2026","bullets":["Revenue $10.1M (+17% YoY); gross margin 80% (vs 62% Q1 2025) from new earnout structure.","Net loss $4.8M ($0.41/shr) vs $4.2M ($0.47/shr); operating loss improved to $4.3M from $4.5M.","Adjusted EBITDA -$3.6M vs -$4.4M; cash consumption near zero; cash $6.3M vs $1.8M Q1 2025.","FDA accepted sNDA for Ameluz PDT for superficial BCC; PDUFA target date Sept 28, 2026.","Positive Phase 3 AK results (primary endpoint met) and Phase 2b acne data (58% lesion reduction); regained Nasdaq compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-022875","json":"https://secwatch.observer/filing/0001493152-26-022875.json","markdown":"https://secwatch.observer/filing/0001493152-26-022875.md","text":"https://secwatch.observer/filing/0001493152-26-022875.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/0001493152-26-022875-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T12:10:23.339612+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}